Limits...
The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.

Schernthaner G, Mogensen CE, Schernthaner GH - Diab Vasc Dis Res (2014)

Bottom Line: Optimal treatment and prevention of DN may require an early, intensive, multifactorial approach, tailored to simultaneously target all modifiable risk factors.Dipeptidyl peptidase (DPP)-4 inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels without additional risk of hypoglycaemia, and may also reduce albuminuria.Further investigation of the potential renal benefits of DPP-4 and SGLT2 inhibitors is underway.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria guntram.schernthaner@meduniwien.ac.at.

Show MeSH

Related in: MedlinePlus

DPP-4 effects beyond glucose lowering.Source: Republished with permission of The Endocrine Society, from Ussher and Drucker.62 ©2014.BNP: B-type (brain) natriuretic peptide; DPP-4: dipeptidyl peptidase-4; GIP: glucose-dependent insulinotropic polypeptide; GLP-1: glucagon-like peptide-1; NPY: neuropeptide; PYY: peptide YY; SDF-1α: stromal cell-derived factor-1α; SP: substance P.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2 - License 3
getmorefigures.php?uid=PMC4230539&req=5

fig2-1479164114542802: DPP-4 effects beyond glucose lowering.Source: Republished with permission of The Endocrine Society, from Ussher and Drucker.62 ©2014.BNP: B-type (brain) natriuretic peptide; DPP-4: dipeptidyl peptidase-4; GIP: glucose-dependent insulinotropic polypeptide; GLP-1: glucagon-like peptide-1; NPY: neuropeptide; PYY: peptide YY; SDF-1α: stromal cell-derived factor-1α; SP: substance P.

Mentions: Incretin-based therapies for the treatment of hyperglycaemia include the injectable GLP-1 receptor agonists and the orally active DPP-4 inhibitors, both of which stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner. Among the substrates of DPP-4 are peptide hormones such as B-type natriuretic peptides, neuropeptide Y, peptide YY and stromal cell-derived factor-1α (Figure 2),62,63 which are thought to be responsible for the cardio-renal effects potentially beneficial for patients with T2DM.63,64


The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.

Schernthaner G, Mogensen CE, Schernthaner GH - Diab Vasc Dis Res (2014)

DPP-4 effects beyond glucose lowering.Source: Republished with permission of The Endocrine Society, from Ussher and Drucker.62 ©2014.BNP: B-type (brain) natriuretic peptide; DPP-4: dipeptidyl peptidase-4; GIP: glucose-dependent insulinotropic polypeptide; GLP-1: glucagon-like peptide-1; NPY: neuropeptide; PYY: peptide YY; SDF-1α: stromal cell-derived factor-1α; SP: substance P.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2 - License 3
Show All Figures
getmorefigures.php?uid=PMC4230539&req=5

fig2-1479164114542802: DPP-4 effects beyond glucose lowering.Source: Republished with permission of The Endocrine Society, from Ussher and Drucker.62 ©2014.BNP: B-type (brain) natriuretic peptide; DPP-4: dipeptidyl peptidase-4; GIP: glucose-dependent insulinotropic polypeptide; GLP-1: glucagon-like peptide-1; NPY: neuropeptide; PYY: peptide YY; SDF-1α: stromal cell-derived factor-1α; SP: substance P.
Mentions: Incretin-based therapies for the treatment of hyperglycaemia include the injectable GLP-1 receptor agonists and the orally active DPP-4 inhibitors, both of which stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner. Among the substrates of DPP-4 are peptide hormones such as B-type natriuretic peptides, neuropeptide Y, peptide YY and stromal cell-derived factor-1α (Figure 2),62,63 which are thought to be responsible for the cardio-renal effects potentially beneficial for patients with T2DM.63,64

Bottom Line: Optimal treatment and prevention of DN may require an early, intensive, multifactorial approach, tailored to simultaneously target all modifiable risk factors.Dipeptidyl peptidase (DPP)-4 inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels without additional risk of hypoglycaemia, and may also reduce albuminuria.Further investigation of the potential renal benefits of DPP-4 and SGLT2 inhibitors is underway.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria guntram.schernthaner@meduniwien.ac.at.

Show MeSH
Related in: MedlinePlus